Navigation Links
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
Date:11/11/2013

ght, Director of Research and Development at GW. "We believe this clinical program demonstrates the flexibility and broad application of GW's cannabinoid platform to treat significant, unmet therapeutic needs." 

This study is a 20-patient, multicentre, two part study with an open-label phase to assess safety and tolerability of GW cannabinoids in combination with temozolomide, and a double blind, randomised, placebo-controlled phase with patients randomised to active or placebo, and with a primary outcome measure of 6 month progression free survival. The study objective is to assess the tolerability, safety and pharmacodynamics of a mixture of two principal cannabinoids, THC and CBD in a 1:1 allocation ratio, in combination with temozolomide in patients with recurrent GBM. Secondary endpoints include additional pharmacokinetic and biomarker analyses and additional measurable outcomes of tumor response.

References:

i. Parolaro D, Massi P, Rubino T, Monti E. Endocannabinoids in the immune system and cancer. Prostaglandins Leukot Essent Fatty Acids 2002;66(2-3):319-32.
ii. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003;3(10):745-55.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 22 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world l
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Baylor Research Institute (BRI) at ... Institute (TGen) in Phoenix, AZ , ... detection and treatments for patients with a broad range of ... to new clinical trials and access to technology to drive ... bench to bedside across Baylor Scott & White ...
(Date:5/21/2015)... YORK , May 21, 2015  Prima Biomed ... company that is striving to become a leader in ... cancer, recently announced that the final CVac data from ... shown a clear trend for a clinically meaningful improvement ... in second remission patients. In the group ...
(Date:5/21/2015)... Patent Offering, The patent’s technology pertains to an ... within a body lumen (open space). Known as ... cost, single-use disposable illumination and camera module (housing). ... and the patent approval was received on January 6, ... the lighting and magnification of the endoscope for different ...
(Date:5/21/2015)... 2015 Veolia’s environmental monitoring technology ... American distribution agreement with VWR to distribute TECTA™ ... more than 160 years of experience, VWR, a ... laboratory and production facilities, has cultivated a value ... services to enable science. Endetec’s TECTA™ B16, ...
Breaking Biology Technology:Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4Correction Continues after Big Move - BrokerBank Securities, Inc. 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
... announced that researchers will present data on several inflammatory ... College of Rheumatology, from October 17 to 21, 2009 ... , "Through our research into novel disease pathways involved ... of using scientific excellence to deliver life-changing medicines for ...
... 15 BioInformatics, LLC announces the pending release of ... Research Products in FY2010. The 8.2 billion ... the American Recovery and Reinvestment Act is being earmarked ... and research that spans multiple public and non-profit institutions, ...
... 15 /PRNewswire-Asia-FirstCall/ -- China Integrated,Energy, Inc. (Nasdaq: CBEH ... China, today announced that it intends to offer,subject to ... stock. The Company intends to grant to the underwriters ... the Company,s common stock to,cover over-allotments, if any. , ...
Cached Biology Technology:MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology 2MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology 3BioInformatics, LLC New Report - The Market Outlook for Research Products in FY2010 2BioInformatics, LLC New Report - The Market Outlook for Research Products in FY2010 3China Integrated Energy, Inc. Announces Eight Million Share Public Follow-On Offering 2China Integrated Energy, Inc. Announces Eight Million Share Public Follow-On Offering 3
(Date:5/6/2015)... , May 6, 2015 LifeBEAM, a developer ... helmet producer, announced today that they will expand their ... world,s first bio-sensing cycling helmet and the first joint ... two new colors in order to give cyclists more ... In addition, LifeBEAM and Lazer announced their plan to ...
(Date:4/27/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... the first week of May, 2015 and will be ... Gino Pereira , Chief Executive ... company as Wocket® enters the consumer market. We would ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial ... Valley to implant a new miniaturized, wireless monitoring sensor ... is the first and only FDA-approved heart failure monitoring ... admissions when used by physicians to manage heart failure. ... that is implanted in the pulmonary artery (PA) during ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... In the animal world, males typically search for their female partners. ... reversalthe females search for males. A new study of ... the Royal Society B co-authored by U of T Mississauga professor ... offer a lot more than just sperm. "In this ...
... defined male or female genitals experience a roller-coaster of emotions, including ... a study in the October issue of the Journal of ... found that they were keen to find a sense of harmony ... as. "The parents we spoke to went through a ...
... from the Walter and Eliza Hall Institute have for ... in parasitic worms that could one day lead to ... and prevalent diseases. Dr Erinna Lee and Dr ... programmed cell death (also called apoptosis) in human cells. ...
Cached Biology News:Sexy snacks 2Parents feel shock, anxiety and the need to protect children with genital ambiguity 2Parents feel shock, anxiety and the need to protect children with genital ambiguity 3Worm 'cell death' discovery could lead to new drugs for deadly parasite 2